Drug information provided by: Merative, Micromedex®
Naxitamab-gqgk injection is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat relapsed (has come back) or refractory (did not respond to previous treatment) high-risk neuroblastoma (a type of cancer that most often occurs in young children) in the bone or bone marrow in patients who have shown a partial response, a minor response, or have stable disease to previous treatment. This medicine is a GD2-binding monoclonal antibody.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
妙佑医疗国际不为任何公司或产品背书。广告收入为我们的非营利使命提供支持。
浏览妙佑医疗国际出版社提供的畅销书以及书籍和简报的特别优惠。
您的捐赠可以抵税。请您慷慨解囊,和我们一起进行尖端研究和医护,共同推动医学的改变。